6-cyano-1-chloro-6-methylheptane | 140660-32-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-cyano-1-chloro-6-methylheptane
• 英文别名: 7-Chloro-2,2-dimethylheptanenitrile
• CAS: 140660-32-8
• 化学式: C₉H₁₆ClN
• 分子量: 173.686
• InChiKey: NNGFBRRUJYGVKS-UHFFFAOYSA-N

物化性质

• 沸点：
  263.4±23.0 °C(Predicted)
• 密度：
  0.954±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-cyano-1-chloro-6-methylheptane 在 叠氮基三甲基硅烷 、 potassium carbonate 、 tetra-n-butylammoniumfluoride trihydrate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 反应 50.0h， 生成 1-[5-乙基-2-羟基-4-[[6-甲基-6-(1H-四唑-5-基)庚基]氧基]苯基]乙酮
  参考文献：
  名称：

  Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists

  摘要：

  Compound 1 (IC50 = 35.2 +/- 7.2 mu M), a moderate FXR antagonist was discovered via high-throughput screening. Structure-activity relationship studies indicated that the shape and the lipophilicity of the substituents of the aromatic ring affect the activity dramatically, increasing the shape and the lipophilicity of the substituents of the aromatic ring enhances the potency of FXR antagonists. Especially, when the OH at C2 position of the aromatic ring was replaced by the OBn substituent (analog 2b), its activity could be improved to IC50 = 1.1 +/- 0.1 mu M. Besides, the length of the linker and the tetrazole structure are essential for retaining the activity. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.032
• 作为产物：
  描述：

  异丁腈 、 1-溴-5-氯戊烷 在 正丁基锂 、 二异丙胺 作用下， 生成 6-cyano-1-chloro-6-methylheptane
  参考文献：
  名称：

  白三烯B4受体拮抗剂：LY255283系列羟基苯乙酮。

  摘要：

  制备了一系列羟基苯乙酮作为白三烯B4（LTB4）受体拮抗剂进行评估，最终以1- [5-乙基-2-羟基-4-[[6-甲基-6-（1H-四唑-5-基）庚基] [氧基]苯基]乙酮（化合物35，LY255283）。使用抑制特异性[3H] LTB4与人PMN结合的测定方法，我们发现活性需要5位非极性取代基的取代。最佳活性是通过3位氢，2位羟基，1位短链烷基酮以及将4位氧与不饱和末端相连的六碳或八碳链实现的功能。选择在结合试验中IC50为87 nM的化合物35进行进一步的临床前评估。

  DOI：

  10.1021/jm00088a018

文献信息

• Leukotriene B4 receptor antagonists: the LY255283 series of hydroxyacetophenones
  作者：David K. Herron、Theodore Goodson、Nancy G. Bollinger、Dorothy Swanson-Bean、Ian G. Wright、Gilbert S. Staten、Alan R. Thompson、Larry L. Froelich、William T. Jackson

  DOI：10.1021/jm00088a018

  日期：1992.5

  A series of hydroxyacetophenones was prepared for evaluation as leukotriene B4 (LTB4) receptor antagonists, culminating in 1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5- yl)heptyl]oxy]phenyl]ethanone (compound 35, LY255283). Using an assay for inhibition of specific [3H]LTB4 binding to human PMN, we found that substitution of a nonpolar substituent in the 5-position was required for activity.

  制备了一系列羟基苯乙酮作为白三烯B4（LTB4）受体拮抗剂进行评估，最终以1- [5-乙基-2-羟基-4-[[6-甲基-6-（1H-四唑-5-基）庚基] [氧基]苯基]乙酮（化合物35，LY255283）。使用抑制特异性[3H] LTB4与人PMN结合的测定方法，我们发现活性需要5位非极性取代基的取代。最佳活性是通过3位氢，2位羟基，1位短链烷基酮以及将4位氧与不饱和末端相连的六碳或八碳链实现的功能。选择在结合试验中IC50为87 nM的化合物35进行进一步的临床前评估。
• Catalytic Decarboxylation/Carboxylation Platform for Accessing Isotopically Labeled Carboxylic Acids
  作者：Andreu Tortajada、Yaya Duan、Basudev Sahoo、Fei Cong、Georgios Toupalas、Antoine Sallustrau、Olivier Loreau、Davide Audisio、Ruben Martin

  DOI：10.1021/acscatal.9b01921

  日期：2019.7.5

  integrated catalytic decarboxylation/carboxylation for accessing isotopically labeled carboxylic acids with 13CO2 or 14CO2 is described. The method shows a wide scope under mild conditions, even in the context of late-stage functionalization, and does not require stoichiometric organometallics, thus complementing existing carbon-labeling techniques en route to carboxylic acids.

  描述了用于访问具有13 CO 2或14 CO 2的同位素标记的羧酸的集成催化脱羧/羧化反应。该方法在温和条件下显示了宽泛的范围，即使在后期功能化的情况下也是如此，并且不需要化学计量的有机金属，因此可以补充现有的碳标记技术（在羧酸生产过程中）。
• Synthetic and Structure/Activity Studies on Acid-Substituted 2-Arylphenols: Discovery of 2-[2-Propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]- propoxy]phenoxy]benzoic Acid, a High-Affinity Leukotriene B4 Receptor Antagonist
  作者：J. Scott Sawyer、Nicholas J. Bach、S. Richard Baker、Ronald F. Baldwin、Peter S. Borromeo、Sandra L. Cockerham、Jerome H. Fleisch、Paul Floreancig、Larry L. Froelich

  DOI：10.1021/jm00022a006

  日期：1995.10

  Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B-4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These new analogues, the subject of a broad structure-activity investigation, displayed significantly increased in vitro and in vivo activity as receptor antagonists of LTB(4). A series of diaryl ether carboxylic acids demonstrated especially interesting activity and led to the discovery of compound 43b, 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]- propoxy]phenoxy]benzoic acid (LY293111), a 2-arylphenol-substituted diaryl ether carboxylic acid which displayed potent binding to human neutrophils (IC50 = 17 +/- 14.6 nM) and guinea pig lung membranes (IC50 6.6 +/- 0.71 nM), inhibition of LTB(4)-induced expression of the CD11b/CD18 receptor on human neutrophils (IC50 - 3.3 +/- 0.81 nM), and inhibition of LTB(4)-induced contraction of guinea pig lung parenchyma (pK(B) = 8.7 +/- 0.16). In vivo, 43b demonstrated potent activity in inhibiting LTB(4)-induced airway obstruction in the guinea pig when dosed by the oral (ED(50) = 0.40 mg/kg) or intravenous (ED(50) = 0.014 mg/kg) routes. A specific LTB(4) receptor antagonist, 43b had little effect on inhibiting contractions of guinea pig lung parenchyma induced by leukotriene D-4 (LTD(4)), histamine, carbachol, or U46619. Compound 43b has been chosen as a clinical candidate and is currently in phase I studies for a variety of inflammatory diseases.
• o-Phenylphenols: potent and orally active leukotriene B4 receptor antagonists
  作者：Michael J. Sofia、Paul Floreancig、Nicholas J. Bach、S. Richard Baker、Sandra L. Cockerham、Jerome H. Fleisch、Larry L. Froelich、William T. Jackson、Philip Marder

  DOI：10.1021/jm00076a029

  日期：1993.11
• 1,2,4-trioxygenated benzene derivatives useful as a leukotriene antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0579412B1

  公开（公告）日：1998-10-07